GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...

Let's discuss whether Vertex Pharmaceuticals stock is a buy now ... Vertex's ongoing effort to reduce its dependence on CF therapies by expanding into new therapeutic areas.